Advanced Solutions
for Advanced Pathology
CA-125 (OC125)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45168 IMPATH CA-125 RTU M (OC125)
50 Tests
44211 CA125 RTU M (OC125)
7 ml Ready To Use
44845 CA125 0,1 M (OC125)
100 µl liquid Concentrated
44447 CA125 1 M (OC125)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic, Membranous
Control
Ovarian Serous Carcinoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
/k
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
CA-125 (cancer antigen 125), also known as mucin 16 or MUC16, is a protein which, in humans, is encoded by the MUC16 gene.
CA-125 is a member of the mucin family of glycoproteins. Anti-CA-125 recognizes specific carbohydrate-associated epitope(s) localized in
the variable region of the cancer cell-expressed immunoglobulin heavy chains. It is best known as a marker for ovarian cancer, but it may also
be detected in other malignancies, including those originating in the endometrium, fallopian tubes, lungs, breast and gastrointestinal tract.
Anti-CA-125 reacts with epithelioid malignancies of the ovary, papillary serous carcinoma of the cervix, adenocarcinoma of the endometrium,
clear cell adenocarcinoma of the bladder, and a minority of epithelioid mesotheliomas. Anti-CA-125 also reacts with antigens in seminal vesicle
carcinoma.
Colon vs. Ovarian Carcinoma
CA-125 CK 7
CK 20
CEA CDX-2
Villin CA19-9 Ep-CAM WT1 CK 5&6
Ovarian Carcinoma, Serous
+
+
-
+
-
+
+
+
+
-
Ovarian Carcinoma,
Mucinous
-
+
-
-
+
+
+
+
-
Ovarian Endometrioid Ca
+
+
-
-
-
+/-
+
+
-
Colorectal Carcinoma
-
-
+
+
+
+
+
+
-
-
Reference
1. Dabawat S, et al. Int J Gyn Path. 1983; 2:275-285.
2. Davis H, et al. Cancer Res. 1986; 46:6143-6148.
3. Nouwen E, et al. Cancer Res. 1986; 46:866-876.
4. Quirk J, et al. J Obst Gyn. 1988; 159:644-649.
5. Fukazawa I, et al. Gynecol Obstet. 1988; 243:41-50.
6. Zhou C, et al. Am J Surg Pathol. 1998 Jan; 22(1):113-20.
7. Mylonas I, et al. Anticancer Res. 2003 Mar-Apr; 23(2A):1075-80.
37
